Dossier assessment
Pomalidomide (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Pomalidomide (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Pomalidomide (multiple myeloma) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with multiple myeloma who have received at least one prior treatment regimen including lenalidomide
Due to negative effects in several side effects hint of lesser benefit than bortezomib and dexamethasone alone
Project details
- Project no.
- A19-50
- Commission
- Commission awarded on 11.06.2019 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Addendum
Pomalidomide (multiple myeloma) - Addendum to Commission A19-50
Status: Commission completed
-
Dossier assessment
Pomalidomide - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pomalidomide - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment))
Status: Commission completed